— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC ...
As of Monday, April 13, Alto Neuroscience, Inc.’s ANRO share price has surged by 6.32%, which has investors questioning if ...
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 ...
It’s ancient, unstoppable and strangely contagious. Here’s what science now knows about the humble yawn, and why evolution ...
Alto Neuroscience, Inc. ( (ANRO)) has shared an announcement. On April 1, 2026, Alto Neuroscience reported topline Phase 2 proof-of-concept data for ALTO-101 in cognitive impairment associated with ...
As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the ...
The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born ...
Detailed price information for Algernon Health Inc A (AGNPF) from The Globe and Mail including charting and trades.
Strong demand for cancer drug Darzalex and psoriasis treatment Tremfya helped offset a steep drop in Stelara sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results